Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2

Wang, Jinyang; Du, Longyuan; Zhang, Tianyun; Chu, Yun; Wang, Yue; Wang, Yu; Ji, Xiaoming; Kang, Yunxiao; Cui, Rui; Zhang, Guoliang; Liu, Junyan; Shi, Geming

doi:10.1016/j.neuropharm.2024.110006

Cited by 1 publication

(1 citation statement)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of clinical and animal studies have shown that edaravone dexborneol alleviated ischemic brain damage by multiple molecular mechanisms including its effect on inflammatory response [ 8 , 12 , 29 – 32 ]. Additionally, a previous study showed that edaravone dexborneol reduced the levels of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in the APP/PS1 mice [ 33 ]. Importantly, edaravone dexborneol also suppressed the production of IL-1β, IL-6 and TNF-α and inhibited macrophages polarization to alleviate ischemic injury [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke

Chen,

Zhang,

et al. 2024

BMC Neurol

View full text Add to dashboard Cite

Background Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient. Methods All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset. Results Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score < 2 compared to those who did not receive this treatment (70.7% versus 47.8%; P = 0.031). Furthermore, individuals receiving edaravone dexborneol injection exhibited lower expression levels of interleukin (IL)-1β, IL-6, and IL-17, along with higher levels of IL-4 and IL-10 expression during the acute phase of ischemic stroke (P < 0.05). These trends were not observed for IL-2, IL-5, IL-8, IL-12p70, tumor necrosis factor-α, interferon-γ [IFN-γ], and IFN-α (P > 0.05). Conclusions Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels. Trial registration ClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.clinicaltrials.gov/ct2/show/NCT04175691.

show abstract